GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioCardia Inc (NAS:BCDA) » Definitions » EBITDA

BioCardia (BioCardia) EBITDA : $-11.56 Mil (TTM As of Dec. 2023)


View and export this data going back to 1996. Start your Free Trial

What is BioCardia EBITDA?

BioCardia's EBITDA for the three months ended in Dec. 2023 was $-2.06 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-11.56 Mil.

During the past 3 years, the average EBITDA Growth Rate was 8.20% per year. During the past 5 years, the average EBITDA Growth Rate was 4.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 13 years, the highest 3-Year average EBITDA Growth Rate of BioCardia was 54.20% per year. The lowest was -72.30% per year. And the median was 2.40% per year.

BioCardia's EBITDA per Share for the three months ended in Dec. 2023 was $-0.09. Its EBITDA per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.55.

During the past 3 years, the average EBITDA per Share Growth Rate was 28.20% per year. During the past 5 years, the average EBITDA per Share Growth Rate was 32.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.

During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of BioCardia was 62.80% per year. The lowest was -72.80% per year. And the median was 34.95% per year.


BioCardia EBITDA Historical Data

The historical data trend for BioCardia's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioCardia EBITDA Chart

BioCardia Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -14.49 -14.93 -12.57 -11.82 -11.56

BioCardia Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.00 -3.49 -3.43 -2.58 -2.06

Competitive Comparison of BioCardia's EBITDA

For the Biotechnology subindustry, BioCardia's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioCardia's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioCardia's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where BioCardia's EV-to-EBITDA falls into.


Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

BioCardia's EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

BioCardia's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Dec. 2023, BioCardia's EBITDA was $-11.56 Mil.

BioCardia's EBITDA for the quarter that ended in Dec. 2023 is calculated as

BioCardia's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Dec. 2023, BioCardia's EBITDA was $-2.06 Mil.

EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.56 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

BioCardia  (NAS:BCDA) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


BioCardia EBITDA Related Terms

Thank you for viewing the detailed overview of BioCardia's EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


BioCardia (BioCardia) Business Description

Traded in Other Exchanges
Address
320 Soquel Way, Sunnyvale, CA, USA, 94085
BioCardia Inc is a clinical stage regenerative medicine company. It is developing therapeutics for cardiovascular and pulmonary diseases with large unmet medical needs. The company is developing comprehensive biotherapeutic candidates for cardiac regenerative medicine namely CardiAMP and CardiALLO, with a focus on heart failure resulting from a heart attack.
Executives
Frost Phillip Md Et Al 10 percent owner 4400 BISCAYNE BLVD, MIAMI FL 33137-3227
Bill Facteau director C/O BIOCARDIA, INC., 320 SOQUEL WAY, SUNNYVALE CA 94085
Frost Gamma Investments Trust 10 percent owner 4400 BISCAYNE BLVD, MIAMI FL 33137
Krisztina M Zsebo director C/O CELLADON CORPORATION, 12760 HIGH BLUFF DRIVE, SUITE 240, SAN DIEGO CA 92130
Edward M Gillis officer: Senior Vice President, Devices C/O BIOCARDIA, INC., 125 SHOREWAY ROAD, SUITE B, SAN CARLOS CA 94070
Andrew Scott Blank director C/O BIOCARDIA, INC., 125 SHOREWAY ROAD, SUITE B, SAN CARLOS CA 94070
Jim L. Allen director C/O BIOCARDIA, INC., 125 SHOREWAY ROAD, SUITE B, SAN CARLOS CA 94070
Simon H Stertzer director C/O BIOCARDIA, INC., 125 SHOREWAY DRIVE, SUITE B, SAN CARLOS CA 94070
Peter Altman director, officer: President and CEO C/O BIOCARDIA INC, 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA 94070
Stertzer Family Trust 10 percent owner C/O BIOCARDIA INC, 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA 94070
Kimberly Stertzer 10 percent owner C/O BIOCARDIA INC, 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA 94070
David Mcclung officer: VP of Finance C/O BIOCARDIA, INC., 125 SHOREWAY ROAD, SUITE B, SAN CARLOS CA 94070
Allan R Tessler director C/O EPOCH HOLDING CORPORATION, 640 FIFTH AVENUE, NEW YORK, NY 10019
Richard T Allen officer: VP, Quality Assurance C/O BIOCARDIA, INC., 125 SHOREWAY ROAD, SUITE B, SAN CARLOS CA 94070
Thomas Quertermous director C/O BIOCARDIA INC, 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA 94070

BioCardia (BioCardia) Headlines

From GuruFocus

BioCardia Letter to Shareholders

By Tiesvg Tiesvg 12-22-2022